| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04721015 | Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors | PHASE1 | ACTIVE NOT_RECRUITING | 81 | — | — | Feb 23, 2021 | Feb 1, 2026 | Jul 3, 2025 | 33 | United States, Australia +6 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.
ORR is defined as the percentage of participants with a confirmed response (CR) or partial response (PR) per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
| Arm | Type | Description |
|---|---|---|
| Part 1: ABBV-637 Monotherapy | EXPERIMENTAL | Participants will receive escalating doses of ABBV-637 in 28-day cycles. |
| Part 2a: ABBV-637 + Docetaxel | EXPERIMENTAL | Participants will receive escalating doses of ABBV-637 in combination with docetaxel in 28-day cycles. |
| Part 2b: ABBV-637 + Docetaxel | EXPERIMENTAL | Participants will receive ABBV-637 at dose determined in Part 2a in combination with docetaxel in 28-day cycles. |
| Part 3a: ABBV-637 + Osimertinib | EXPERIMENTAL | Participants will receive escalating doses of ABBV-637 in combination with osimertinib in 28-day cycles. |
| Part 3b: ABBV-637 + Osimertinib | EXPERIMENTAL | Participants will receive ABBV-637 at dose determined in Part 3a in combination with osimertinib in 28-day cycles. |
| Name | Type | Description |
|---|---|---|
| ABBV-637 | DRUG | Intravenous (IV) Infusion |
| Docetaxel | DRUG | Intravenous (IV) Infusion |
| Osimertinib | DRUG | Oral Tablets |
Inclusion Criteria: * Histologic solid tumor diagnosis (Part 1). * For Part 2 docetaxel combination therapy: EGFR WT expressing relapsed/refractory (R/R) non-small cell lung cancer (NSCLC) participants. * For Part 3 osimertinib combination therapy: mutEGFR-expressing RR NSCLC participants. * Measur...